Abstract: Objective To explore the clinical efficacy and adverse reactions of Bortezomib-containing combination chemotherapy on multiple myeloma. Methods Total 35 cases of multiple myeloma treated with Bortezomib in Taizhou Hospital from January,2009 to June,2014 were enrolled and divided into newly diagnosed group and relapsed group that including ≥ 4 cycles group and <4 cycle group.The curative efficacy,2-year overall survival and progression-free survival at 2 years,and chemotherapy adverse reactions of the each groups were observed. Results The efficacy of newly diagnosed group was superior than that of the relapsed group(Z=-0.842,P=0.004).The efficacy of ≥ 4 cycles group was superior than that of <4 cycle groups(Z=-2.224,P=0.026).2-year overall survival was closely related to ISS staging and efficacy(P<0.05),there was no significant correlation with pre-treatment status and extramedullary lesion(P>0.05).The progression-free survival at 2 years was closely related to extramedullary disease(P<0.05) and was no significant correlation with the pre-treatment state,ISS staging and efficacy(P>0.05).In 35 cases of multiple myeloma,14 cases were with gastrointestinal symptoms,13 cases with peripheral neuropathy,21 cases with thrombocytopenia,and 13 cases with leukopenia. Conclusion The therapeutic effect of bortezomib-containing combination chemotherapy for multiple myeloma is more precise,especially for the newly diagnosed patients.The treatment of more than four cycles is usually with a better efficacy,and adverse reactions can also be tolerated.